SCHEMBL7101509

SCHEMBL7101509

Oc1ccccc1Cc1ccccc1Cl

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSPA5 P11021 2/20 0.73
ALDH1A1 P00352 1/20 0.54
KEAP1 Q14145 1/20 0.52
IDO1 P14902 2/20 0.48
PNMT P11086 1/20 0.48
HIF1A Q16665 2/20 0.46
TSHR P16473 2/20 0.46
CYP2D6 P10635 1/20 0.46
TAAR1 Q96RJ0 3/20 0.45
PKM P14618 1/20 0.45
HSP90AA1 P07900 2/20 0.45
AKR1B1 P15121 1/20 0.45
MEN1 O00255 1/20 0.45
SLC22A1 O15245 1/20 0.45
USP2 O75604 1/20 0.45
LMNA P02545 1/20 0.45
CYP3A4 P08684 1/20 0.45
MAPT P10636 1/20 0.45
HSPD1 P10809 1/20 0.45
HPGD P15428 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL49745 0.85 HSPA5 (1.00) HSPA5ALDH1A1KEAP1IDO1HIF1A
SCHEMBL10470450 0.85 HSPA5 (0.64) HSPA5ALDH1A1KEAP1IDO1HIF1A
SCHEMBL29519238 0.85 IDO1 (0.62) IDO1PNMTTSHRCYP2D6TAAR1
SCHEMBL29357407 0.85 HSPA5 (1.00) HSPA5ALDH1A1KEAP1IDO1HIF1A
SCHEMBL672407 0.85 IDO1 (0.62) IDO1PNMTTSHRCYP2D6TAAR1
SCHEMBL2305654 0.84 HSPA5 (0.61) HSPA5ALDH1A1KEAP1IDO1PNMT
SCHEMBL16637058 0.83 HSPA5 (0.55) HSPA5ALDH1A1KEAP1IDO1PNMT
SCHEMBL29839938 0.83 HSPA5 (0.94) HSPA5ALDH1A1KEAP1IDO1HIF1A
Ammonia Solution, Strong SCHEMBL28323965 0.83 HSPA5 (0.94) HSPA5ALDH1A1KEAP1IDO1HIF1A
SCHEMBL7809667 0.83 HSPA5 (0.94) HSPA5ALDH1A1KEAP1IDO1HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12590963-B2 Anti-cancer treatment of preselected subjects and screening methods to identify susceptible subjects TUDAG TU DRESDEN AKTIENGESELLSCHAFT (DE) 2026-03-31 US disclosed
EP-3803402-B1 ANTI-CANCER TREATMENT OF PRESELECTED SUBJECTS AND SCREENING METHODS TO IDENTIFY SUSCEPTIBLE SUBJECTS TUDAG TU DRESDEN AG (DE) 2023-04-26 EP disclosed
EP-3578981-B1 ANTI-CANCER TREATMENT OF PRESELECTED SUBJECTS AND SCREENING METHODS TO IDENTIFY SUSCEPTIBLE SUBJECTS TUDAG TU DRESDEN AG (DE) 2021-10-27 EP disclosed
US-20210231661-A1 ANTI-CANCER TREATMENT OF PRESELECTED SUBJECTS AND SCREENING METHODS TO IDENTIFY SUSCEPTIBLE SUBJECTS TUDAG TU DRESDEN AKTIENGESELLSCHAFT (DE) 2021-07-29 US disclosed
EP-3803402-A1 ANTI-CANCER TREATMENT OF PRESELECTED SUBJECTS AND SCREENING METHODS TO IDENTIFY SUSCEPTIBLE SUBJECTS Tudag Tu Dresden Aktiengesellschaft (DE) 2021-04-14 EP disclosed
CN-112534265-A Screening method for preselecting individual for anti-cancer treatment and identifying individual susceptible to disease TUDAG德累斯顿工业大学股份公司 2021-03-19 CN disclosed
WO-2019233779-A1 ANTI-CANCER TREATMENT OF PRESELECTED SUBJECTS AND SCREENING METHODS TO IDENTIFY SUSCEPTIBLE SUBJECTS Technische Universität Dresden (DE) 2019-12-12 WO disclosed
US-20030207782-A1 Aqueous organic dispersions suitable for removing organic films and soils ECOLAB INC. 2003-11-06 US disclosed
US-6583101-B1 Synergystic solvent concentrates comprising carbo and acyclic hydroxy ethers, used as antisoilants for substrate surfaces such as floors, photoresists, paints, inks, woven or nonwoven fabrics ECOLAB INC. 2003-06-24 US disclosed
US-4506103-A Process for the preparation of o-benzylphenol BAYER AKTIENGESELLSCHAFT (DE) 1985-03-19 US disclosed
US-4506103-A Process for the preparation of o-benzylphenol BAYER AKTIENGESELLSCHAFT (DE) 1985-03-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12590963-B2 Anti-cancer treatment of preselected subjects and screening methods to identify susceptible subjects TPM4, TPM3, TAGLN2 HSPA5 1582/4885ALDH1A1 2279/4885KEAP1 1845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.